BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 19857152)

  • 1. Bendamustine: a new treatment option for chronic lymphocytic leukemia.
    Glode AE; Jarkowski A
    Pharmacotherapy; 2009 Nov; 29(11):1375-84. PubMed ID: 19857152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bendamustine in the treatment of chronic lymphocytic leukemia.
    Knauf W
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):165-74. PubMed ID: 19192955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
    Ujjani C; Cheson BD
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1353-65. PubMed ID: 20836669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine: new perspective for an old drug in lymphoproliferative disorders.
    Montillo M; Ricci F; Tedeschi A; Vismara E; Morra E
    Expert Rev Hematol; 2010 Apr; 3(2):131-48. PubMed ID: 21083456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
    Knauf WU; Lissichkov T; Aldaoud A; Liberati A; Loscertales J; Herbrecht R; Juliusson G; Postner G; Gercheva L; Goranov S; Becker M; Fricke HJ; Huguet F; Del Giudice I; Klein P; Tremmel L; Merkle K; Montillo M
    J Clin Oncol; 2009 Sep; 27(26):4378-84. PubMed ID: 19652068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bendamustine: rebirth of an old drug.
    Cheson BD; Rummel MJ
    J Clin Oncol; 2009 Mar; 27(9):1492-501. PubMed ID: 19224851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bendamustine therapy in chronic lymphocytic leukemia.
    Masiello D; Tulpule A
    Expert Opin Pharmacother; 2009 Jul; 10(10):1687-98. PubMed ID: 19527193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
    Bremer K
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bendamustine: a novel cytotoxic agent for hematologic malignancies.
    Blumel S; Goodrich A; Martin C; Dang NH
    Clin J Oncol Nurs; 2008 Oct; 12(5):799-806. PubMed ID: 18842536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
    Roué G; López-Guerra M; Milpied P; Pérez-Galán P; Villamor N; Montserrat E; Campo E; Colomer D
    Clin Cancer Res; 2008 Nov; 14(21):6907-15. PubMed ID: 18980985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bendamustine's emerging role in the management of lymphoid malignancies.
    Rummel MJ; Gregory SA
    Semin Hematol; 2011 Apr; 48 Suppl 1():S24-36. PubMed ID: 21530769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century.
    Leoni LM
    Semin Hematol; 2011 Apr; 48 Suppl 1():S4-11. PubMed ID: 21530771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
    Sanchez-Gonzalez B; Peñalver FJ; Medina A; Guillén H; Calleja M; Gironella M; Arranz R; Sebastian E; de Oña R; Cánovas A; de la Fuente I; Grande C; Sancho JM; Perez R; Domingo E; Lopez-Lorenzo JL; Prieto E; Panizo C; Gorosquieta A; Perez I; Cervera JM; Marin M; Mencha C; Ramila E; Salar A
    Leuk Res; 2012 Jun; 36(6):709-14. PubMed ID: 22154023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.
    Bergmann MA; Goebeler ME; Herold M; Emmerich B; Wilhelm M; Ruelfs C; Boening L; Hallek MJ;
    Haematologica; 2005 Oct; 90(10):1357-64. PubMed ID: 16219572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bendamustine (Treanda) for CLL and NHL.
    Med Lett Drugs Ther; 2008 Nov; 50(1299):91-2. PubMed ID: 19008789
    [No Abstract]   [Full Text] [Related]  

  • 17. Bendamustine: a new look at an old drug.
    Kalaycio M
    Cancer; 2009 Feb; 115(3):473-9. PubMed ID: 19117340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    Elefante A; Czuczman MS
    Am J Health Syst Pharm; 2010 May; 67(9):713-23. PubMed ID: 20410545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia.
    Goldschmidt N; Gural A; Ben-Yehuda D; Gatt ME
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):709-13. PubMed ID: 23907444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial.
    Ujjani C; Cheson B
    Future Oncol; 2011 Jan; 7(1):9-14. PubMed ID: 21174533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.